RxDoctor Payments DataLook up a doctor →

Kendrick Henderson, MD

Neurology · Cordova, TNNPI 1760452577

Payments from drug & device makers

$1,709,549in general payments, 2019–2025

Across 1,910 payments — averaging $895.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.2M
  • E.r. Squibb & Sons, L.L.C.$508K
  • AbbVie$3K
  • UCB, Inc.$1K
  • Amgen$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • plus $18K from 54 others

What the payments were for

  • Speaking & faculty fees$1951%
  • Travel & lodging$9623%
  • Food & beverage$26,99995%
  • Education$2401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis149$1,176,199
E.r. Squibb & Sons, L.L.C.13$508,305
AbbVie(2 entities)351$3,128
UCB, Inc.63$1,352
Amgen(2 entities)70$1,322
Teva Pharmaceuticals USA, Inc.81$1,157
EMD Serono, Inc.105$1,101
Pfizer112$1,100
Biogen66$1,039
AstraZeneca(2 entities)54$944
Genentech USA, Inc.68$896
Lilly USA, LLC55$745
SK Life Science, Inc.41$674
Bristol Myers Squibb42$655
Lundbeck LLC38$641
Argenx US, Inc.29$602
Eisai Inc.30$595
Acadia Pharmaceuticals Inc35$569
MDD US Operations, LLC29$485
Neurocrine Biosciences, Inc.25$481
Amneal Pharmaceuticals LLC30$461
TG Therapeutics, Inc.19$419
Acorda Therapeutics, Inc21$401
Avanir Pharmaceuticals, Inc.23$394
Alnylam Pharmaceuticals Inc.19$360
ANI Pharmaceuticals, Inc.9$327
CSL Behring21$326
Supernus Pharmaceuticals, Inc.37$323
Sanofi16$305
Sunovion Pharmaceuticals Inc.24$293
Biohaven Pharmaceutical Holding Company Ltd.19$254
Otsuka America Pharmaceutical, Inc.18$248
Tanabe Pharma America, Inc.15$238
Grifols USA, LLC13$229
Harmony Biosciences LLC10$224
Akcea Therapeutics, Inc.11$208
Adamas Pharmaceuticals, Inc.11$194
Upsher-smith Laboratories LLC13$185
Johnson & Johnson(2 entities)11$182
Neurelis, Inc.10$172
Abbott5$170
Biohaven Pharmaceuticals, Inc.14$161
Banner Life Sciences, LLC10$157
Jazz Pharmaceuticals Inc.8$156
Kyowa Kirin, Inc.9$131
Catalyst Pharmaceuticals, Inc.6$94
Boston Scientific5$84
Genentech, Inc.2$80
Vanda Pharmaceuticals Inc.5$79
Mallinckrodt Hospital Products Inc.4$77
Insightec,inc1$67
Avion Pharmaceuticals4$61
Axsome Therapeutics, Inc.2$53
Merz Pharmaceuticals, LLC2$51
GE HealthCare3$51
Mallinckrodt Enterprises LLC3$46
C2n Diagnostics, LLC3$42
Sanofi-aventis U.S. LLC2$31
Ipsen Biopharmaceuticals, Inc1$25
Greenwich Biosciences, Inc.2$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,709,549 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$245,237
Medicare patients
727
Services billed
13,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5016$207,662
IngrezzaValbenazine Tosylate12$98,639
Glatiramer Acetate17$51,731
Aimovig AutoinjectorErenumab-Aooe48$38,673
UbrelvyUbrogepant20$19,594
RytaryCarbidopa/Levodopa20$16,897
Memantine Hcl ErMemantine Hcl84$16,135
QuliptaAtogepant11$11,608
Memantine Hcl387$10,075
Ajovy AutoinjectorFremanezumab-Vfrm14$10,019
Emgality PenGalcanezumab-Gnlm12$8,448
Rivastigmine28$7,860
Carbidopa-LevodopaCarbidopa/Levodopa211$6,305
Galantamine ErGalantamine Hbr58$5,289
Gabapentin347$5,237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$481$98,63912 claims
AbbVieUbrelvy, Qulipta$3,128$31,20331 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$461$18,08538 claims
Upsher-smith Laboratories LLCTopiramate$185$48836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.

Other neurology in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →